Skip to content

The moisturizing, soothing, repairing, firming, anti wrinkle, mild effects and safety study of 'WMJ RECOMBINANT HUMANIZED COLLAGEN DRESSING, WMJ RECOMBINANT HUMANIZED COLLAGEN III LIQUID DRESSING, WMJ MULTI-REVITALIZE SERUM, WMJ MULTI-REVITALIZE CREAM'

The moisturizing, soothing, repairing, firming, anti wrinkle, mild effects and safety study of 'WMJ RECOMBINANT HUMANIZED COLLAGEN DRESSING, WMJ RECOMBINANT HUMANIZED COLLAGEN III LIQUID DRESSING, WMJ MULTI-REVITALIZE SERUM, WMJ MULTI-REVITALIZE CREAM'

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094910
Enrollment
Unknown
Registered
2024-12-30
Start date
2024-12-31
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sensitive skin

Interventions

experimental group:experimental products
control group:control product (placebo)

Sponsors

The Third Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Healthy individuals aged 18 to 60, regardless of gender; 2. Those who have dull facial skin, mild or severe wrinkles, enlarged pores, and are willing to undergo dot matrix laser treatment; 3. Participants who voluntarily participate in this trial and are able to sign an informed consent form; 4. Those who can cooperate well with the experimenter and avoid UV radiation during the research period to maintain a regular lifestyle.

Exclusion criteria

Exclusion criteria: 1. The presence of severe bacterial, viral, or fungal infections, as well as other skin problems such as scars and hirsutism on the skin of the facial area, can affect the results of observation; 2. Highly sensitive individuals and those known to be allergic to the ingredients of this product; 3. Individuals with a history of photosensitive diseases and using drugs that affect photosensitivity within the past two months; 4. Those with severe damage to heart, liver, and kidney functions, as well as severe immune dysfunction; 5. Individuals with mental illness and severe endocrine disorders; 6. Pregnant, breastfeeding, or pregnant women planned during the trial period; 7. Have taken oral or topical anti-inflammatory drugs such as corticosteroids in the past two weeks; 8. Those who have participated in any clinical trial or similar trial within the past 3 months; 9. The researcher believes that other subjects are not suitable for this study.

Design outcomes

Primary

MeasureTime frame
skin barrier repair efficacy;Soothing effects;Skin Transepidermal water loss (TEWL) ;Skin surface hydration;skin pH value;Skin Color Lab Value;skin redness and melanin value;skin elasticity (R2 and F4);skin glossiness;skin temperature;

Secondary

MeasureTime frame
auxiliary laser wrinkle removal effect;auxiliary laser shrinkage effect on pores;auxiliary laser skin brightening effect;

Countries

China

Contacts

Public ContactLai Wei

The Third Affiliated Hospital of Sun Yat-sen University

pifuke03@163.com+86 20 8525 3229

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026